MA50908A - Formulations de protéines de fusion vegfr-fc - Google Patents
Formulations de protéines de fusion vegfr-fcInfo
- Publication number
- MA50908A MA50908A MA050908A MA50908A MA50908A MA 50908 A MA50908 A MA 50908A MA 050908 A MA050908 A MA 050908A MA 50908 A MA50908 A MA 50908A MA 50908 A MA50908 A MA 50908A
- Authority
- MA
- Morocco
- Prior art keywords
- vegfr
- fusion protein
- protein formulations
- formulations
- fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587733P | 2017-11-17 | 2017-11-17 | |
| US201862618904P | 2018-01-18 | 2018-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50908A true MA50908A (fr) | 2020-09-23 |
Family
ID=65041879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050908A MA50908A (fr) | 2017-11-17 | 2018-11-16 | Formulations de protéines de fusion vegfr-fc |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12156900B2 (fr) |
| EP (1) | EP3709971A2 (fr) |
| JP (2) | JP7536640B2 (fr) |
| AU (2) | AU2018368466B2 (fr) |
| CA (1) | CA3082899A1 (fr) |
| MA (1) | MA50908A (fr) |
| MX (2) | MX2020005170A (fr) |
| WO (1) | WO2019099921A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| EP3761953A1 (fr) | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Formulations aqueuses stables d'aflibercept |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020055123A1 (fr) | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | Composition liquide comprenant une protéine |
| WO2021050687A1 (fr) * | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Formulations aqueuses stables d'aflibercept |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CA3190325A1 (fr) * | 2020-07-31 | 2022-02-03 | Celltrion Inc. | Preparation pharmaceutique stable |
| US20240166718A1 (en) * | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| WO2025227916A1 (fr) | 2024-04-29 | 2025-11-06 | 齐鲁制药有限公司 | Composition comprenant de l'aflibercept et un variant de celui-ci, son procédé associé et son utilisation |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| JP2026054929A (ja) | 2024-09-17 | 2026-03-30 | キオクシア株式会社 | メモリシステムおよび制御方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CA2654510C (fr) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du vegf appropriees a une administration intravitreenne |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN103816115B (zh) | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| JP6313712B2 (ja) | 2011-12-21 | 2018-04-18 | アムジエン・インコーポレーテツド | 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| AU2013267310A1 (en) | 2012-06-01 | 2014-12-11 | Ophthotech Corporation | Compositions comprising an anti-PDGF aptamer and a VEGF antagonist |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| WO2014078627A1 (fr) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | Formulations liquides pour des protéines de fusion tnfr:fc |
| CA2926853C (fr) | 2013-10-18 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Methodes et compositions comprenant une combinaison d'antagoniste du vegf et d'anticorps anti-ctla-4 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| EP3362041B1 (fr) | 2015-10-16 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | Compositions protéiniques stables |
| ES2981791T3 (es) | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| US10576128B2 (en) | 2016-01-26 | 2020-03-03 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| EP3436473A4 (fr) | 2016-03-29 | 2019-10-23 | Navya Biologicals Pvt. Ltd. | Procédé de purification de protéines de fusion fc |
| KR101685532B1 (ko) | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| EP3518971A4 (fr) | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| JP7116059B2 (ja) | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| CR20190291A (es) | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| WO2019020777A1 (fr) | 2017-07-26 | 2019-01-31 | Formycon Ag | Formulation liquide d'un antagoniste du vegf |
| US20200255496A1 (en) | 2017-09-18 | 2020-08-13 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| CN107595765A (zh) | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | 一种眼用缓释药物递送系统及其制备方法 |
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| WO2019124946A1 (fr) | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Composition liquide comprenant un antagoniste du vegf |
| EP3761953A1 (fr) * | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Formulations aqueuses stables d'aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| WO2020055123A1 (fr) | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | Composition liquide comprenant une protéine |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| EP3923907B1 (fr) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions et procédés pour le traitement de la néovascularisation oculaire |
| GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| WO2021050687A1 (fr) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Formulations aqueuses stables d'aflibercept |
-
2018
- 2018-11-16 MX MX2020005170A patent/MX2020005170A/es unknown
- 2018-11-16 MA MA050908A patent/MA50908A/fr unknown
- 2018-11-16 CA CA3082899A patent/CA3082899A1/fr active Pending
- 2018-11-16 US US16/764,463 patent/US12156900B2/en active Active
- 2018-11-16 AU AU2018368466A patent/AU2018368466B2/en active Active
- 2018-11-16 EP EP18836718.9A patent/EP3709971A2/fr active Pending
- 2018-11-16 WO PCT/US2018/061644 patent/WO2019099921A2/fr not_active Ceased
- 2018-11-16 JP JP2020527828A patent/JP7536640B2/ja active Active
-
2020
- 2020-07-13 MX MX2025004779A patent/MX2025004779A/es unknown
-
2024
- 2024-07-31 AU AU2024205240A patent/AU2024205240A1/en active Pending
- 2024-08-06 JP JP2024129687A patent/JP2024160287A/ja active Pending
- 2024-11-25 US US18/959,137 patent/US20250082726A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3709971A2 (fr) | 2020-09-23 |
| JP7536640B2 (ja) | 2024-08-20 |
| WO2019099921A3 (fr) | 2019-06-27 |
| US12156900B2 (en) | 2024-12-03 |
| JP2021503485A (ja) | 2021-02-12 |
| CA3082899A1 (fr) | 2019-05-23 |
| JP2024160287A (ja) | 2024-11-13 |
| MX2020005170A (es) | 2020-10-16 |
| US20250082726A1 (en) | 2025-03-13 |
| AU2024205240A1 (en) | 2024-08-22 |
| MX2025004779A (es) | 2025-05-02 |
| AU2018368466A1 (en) | 2020-06-18 |
| AU2018368466B2 (en) | 2024-06-20 |
| US20200338164A1 (en) | 2020-10-29 |
| WO2019099921A2 (fr) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50908A (fr) | Formulations de protéines de fusion vegfr-fc | |
| EP3880814A4 (fr) | Protéine de fusion | |
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| EP3519442A4 (fr) | Protéines de fusion immunomodulatrices | |
| IL262652A (en) | Gdf15 fusion proteins and uses thereof | |
| DK3292141T3 (da) | Fusionsproteiner | |
| EP3589662A4 (fr) | Protéine monovalente inductible de fixation d' antigène | |
| PT3649151T (pt) | Proteínas de suporte | |
| MA50657A (fr) | Formulations de niraparib | |
| DK3197453T3 (da) | Kimært protein | |
| DK3180363T3 (da) | Sirp-alpha-immunoglobulin fusionsproteiner | |
| MA50174A (fr) | Formules de protéines de fusion vegfr-fc | |
| DK3107562T3 (da) | P97-ids-fusionsproteiner | |
| EP3344278A4 (fr) | Protéines de fusion immunoglobuline-insuline | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| EP3437776A4 (fr) | Structure de joint | |
| ZA202003845B (en) | Fusion proteins | |
| EP3368012A4 (fr) | Formulations de lisinopril | |
| EP3801605A4 (fr) | Formulation de protéine de fusion stable | |
| DK3608334T3 (da) | Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf | |
| EP3419651C0 (fr) | Formulation de la protéine de fusion naglu améliorée | |
| EP3688037A4 (fr) | Protéines de fusion immunomodulatrices | |
| IL280906A (en) | Formulations of ag10 | |
| EP3463414C0 (fr) | Interfaces de protéines |